Enzene Biosciences Invests $50 Million into New Jersey Biomanufacturing Facility

Article

India’s Enzene Biosciences is investing $50 Million into a new biopharma manufacturing plant in Hopewell, NJ.

Choose New Jersey, a nonprofit economic development organization for the state of New Jersey, announced on June 15, 2023 that Enzene Biosciences, a Pune, India-based biotech company will invest $50 million to open a new biopharmaceutical manufacturing plant on the Princeton West Innovation Campus in Hopewell, NJ. The facility is expected to start up in June 2024 and is the company’s first location outside of India, according to a press release issued by the nonprofit.

Enzene is a contract development and manufacturing organization and a subsidiary of Alkem Laboratories, an Indian pharmaceutical company. As part its expansion plans, Enzene will initially hire 50 employees and grow to 300 employees at the New Jersey facility.

The placement of the facility is intended to provide North American biopharmaceutical companies with streamlined supply chains, quick turnaround times, enhanced communication, and greater control over the manufacturing process, according to the press release. Enzene expects to support the development and production of a diverse range of biologics at the facility.

“The strong relationship between New Jersey and India has gained increasing momentum since we opened the New Jersey India Center to cultivate economic opportunities during our trip to the country in 2019,” said NJ Governor Phil Murphy, in the press release. “I am proud to welcome Enzene Biosciences and their expanding global presence to New Jersey’s flourishing life sciences industry. New Jersey’s favorable business environment, skilled workforce, strategic location, supportive ecosystem for growth, and deep cultural ties are why Indian companies thrive in our state.”

“Enzene Biosciences is thrilled to establish our manufacturing operations in New Jersey, as it allows us to extend our local manufacturing capabilities to our valued North American clients,” said Himanshu Gadgil, CEO of Enzene Biosciences, in the release. “We are excited to provide them with access to our cutting-edge continuous manufacturing platform, which enables streamlined and efficient production processes. New Jersey’s highly skilled workforce, state-of-the-art infrastructure, and renowned academic institutions make it an ideal location for Enzene, ensuring that we can deliver exceptional services and support to our clients in the [United States].”

Source: Choose New Jersey

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Related Content